ZEISS Medical Technology announced the successful early clinical implantations of the ZEISS AT LUCIA toric 721P intraocular lens (IOL), designed to treat cataracts while simultaneously correcting astigmatism. ZEISS is currently conducting an early-access clinical trial with a select group of highly experienced surgeons from six countries across Europe (Czech Republic, Germany, Italy, Spain, Sweden and UK). Surgeons who have begun implanting the new lens have already reported positive early impressions.
“The overwhelmingly positive feedback we’ve received from surgeons strongly validates our optics leadership in the IOL market. The ZEISS AT LUCIA toric 721P raises the bar for precision, stability, and ultimately positive surgical outcomes. This is a new era for IOL technology and ZEISS is at the forefront,” says Frank Seitzinger, Head of Business Sector Surgery Anterior Segment, ZEISS Medical Technology.
The ZEISS AT LUCIA toric 721P IOL will first be showcased at the International Congress of German Ophthalmic Surgery (DOC) in Nuremberg, Germany, from June 18 – 20, 2026. Currently CE marked, the lens is expected to be commercially available in select European countries later in 2026.
Early impressions from surgeons
“Being the first surgeon worldwide to implant the ZEISS AT LUCIA toric 721P was a privilege. The lens combines precision, stability and excellent surgical handling. And in modern cataract surgery, precision matters more than ever. Based on my first experience, the ZEISS AT LUCIA toric 721P has all the ingredients of a true game changer for refractive outcomes,” says Dr. Andrea Janeková, Ph.D., FEBO, FEBOS-CR, Head of the Center for Cataract, Refractive and Vitreoretinal Surgery at Eye Center Prague, Czech Republic.
“With more than 60,000 ZEISS CT LUCIA implantations since Südblick Augenzentren started adopting the lens 12 years ago, I am very excited to be one of the first surgeons globally to implant the ZEISS AT LUCIA toric 721P. The excellent biomaterial and stability of the lens platform is crucial for me as a surgeon. With the ZEISS AT LUCIA toric 721P my first patients have stable refraction combined with very good visual outcomes. I hope to further confirm in the near future that the LUCIA family provides equivalent outcomes,” says Dr. med. Felix Rombold, Chief Medical Officer and CEO, Augenzentren Südblick, Augsburg, Germany.
“Compared with other toric IOLs, the main advantages of the ZEISS AT LUCIA toric 721P are its platform, its bitoric design, and its outstanding rotational stability. I expect this lens to enhance the predictability of refractive outcomes in my practice. Its proven platform gives me confidence in achieving reliable visual results for my patients,” says Dr. Helena Noguera, MD, Department of Refractive and Phaco-Refractive Surgery at Miranza COI Bilbao, Department of Anterior Segment and Glaucoma at Galdácano-Usansolo University Hospital, Bizkaia, Spain.
“Based on my early experience, the AT LUCIA toric 721P with a non-constant aspheric profile truly enhances the quality of vision for patients. The step-vaulted profile and enhanced haptic-optic junction improves the rotational stability of this new toric IOL,” says Prof. Sathish Srinivasan, FRCSEd, FRCOphth, FACS, FWCRS, FEBOS – CR (Hon), Founder and Medical Director, Ayrshire Eye Clinic, Ayr, Scotland, UK.
“The ZEISS AT LUCIA toric 721P stands out for its stability, ease of implantation, and consistent visual outcomes, which have been impressive in my initial experience. I expect this lens to expand our treatment options and help more patients achieve excellent vision with greater confidence and satisfaction,” says Dr. Amin-Robert Kassem, Chief Physician & Clinic Owner, Värnamo Eye Center, Sweden.
For more information about the clinical trials and surgeons’ early implantation success of the ZEISS AT LUCIA toric 721P, visit zeiss.com/at-lucia-toric.
